Lentinan combined with cisplatin and paclitaxel in the treatment of patients with ovarian cancer with ascites

Objective: To observe the clinical efficacy of lentinan combined with cisplatin and paclitaxel in the treatment of ovarian cancer with ascites. Materials and Methods: Two hundred and twelve cases of patients with epithelial ovarian cancer (EOC) and ascites were retrospectively analyzed. Patients were divided into TP (taxinol + platinol) group and TP + lentinan group according to the chemotherapy regimen. Results: The effective rate (CR + PR) in TP group (98 cases) was 31.6% and disease control rate (CR +PR + SD) was 80.6%. The effective rate in TP + lentinan group (114 cases) was 50.9% and the disease control rate was 88.6%, with statistical difference compared with TP group. The control of ascites in TP + lentinan group was better than TP group. The common adverse reactions of chemotherapy in TP + lentinan group was relative mild with reduced incidence. Conclusion: Lentinan combined with chemotherapy could enhance the efficacy of chemotherapy and control of the ascites.

Epithelial ovarian cancer; Lentinan; Taxinol; Platinol; Therapeutic effect.

[1] Kaye S.B.: “Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years”. Ann.

Oncol., 2016, 27, i1.

[2] Hu C., Hart S.N., Bamlet W.R., Moore R.M., Nandakumar K., Eckloff B.W., et al.: “Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients”. Cancer Epidemiol. Biomarkers Prev., 2016, 25, 207.

[3] Jorge S., Jones N.L., Chen L., Hou J.Y., Tergas A.I., Burke W.M., et al.: “Characteristics, treatment and outcomes of women with immature ovarian teratoma, 1998-2012”. Gynecol. Oncol., 2016, 142, 261.

[4] Furnes B., Svensen R., Helland H., Ovrebo K.: “Challenges and outcome of surgery for bowel obstruction in women with gynaecologic cancer”. Int. J. Surg., 2016, 27, 158.

[5] Kim S., Kim B., Song Y.S.: “Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer”. Cancer Sci, 2016, 107, 1173-1178.

[6] Dottino J.A., Cliby W.A., Myers E.R., Bristow R.E., Havrilesky L.J.: “Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention”. Gynecol. Oncol., 2015, 138, 694.

[7] Heery C.R., Ibrahim N.K., Arlen P.M., Mohebtash M., Murray J.L., Koenig K., et al.: “Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial”. JAMA Oncol., 2015, 1, 1087.

[8] Kodera Y., Takahashi N., Yoshikawa T., Takiguchi N., Fujitani K., Ito Y., et al.: “Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial”. Gastric Cancer, 2017, 20, 190.

[9] Wang J., Zhou Z.D., Xia D.J.: “Study on effect of lentinan in enhancing anti-tumor action of dendritic cytoma vaccine and its mechanism]”. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2007, 27, 60.

[10] Ina K., Kataoka T., Ando T.: “The use of lentinan for treating gastric cancer”. Anticancer Agents Med. Chem., 2013, 13, 681.

[11] Wasser S.P.: “Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides”. Appl. Microbiol. Biotechnol., 2002, 60, 258.

[12] Bao L., Wang Y., Ma R., Ren X., Cheng R., B.A.: “Apoptosis-inducing effects of lentinan on the proliferation of human bladder cancer T24 cells”. Pak. J. Pharm. Sci., 2015, 28, 1595.

[13] Oba K., Kobayashi M., Matsui T., Kodera Y., Sakamoto J.: “Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer”. Anticancer Res., 2009, 29, 2739.

[14] Tsuboi, M., Kato H., Nagai K., Tsuchiya R., Wada H., Tada H., et al.: “Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer”. Anticancer Drugs, 2005, 16, 1123.

[15] Openshaw M.R., Fotopoulou C., Blagden S., Gabra H.: “The next steps in improving the outcomes of advanced ovarian cancer”. Womens Health (Lond.), 2015, 11, 355.

[16] Cowan R.A., O’Cearbhaill R.E., Gardner G.J., Levine D.A., Roche K.L., Sonoda Y., et al.: “Is it time to centralize ovarian cancer care in the United States?” Ann. Surg. Oncol., 2016, 23, 989.

[17] Lewellen K.A., Metzinger M.N., Liu Y., Stack M.S.: “Quantitation of intra-peritoneal ovarian cancer metastasis”. J. Vis. Exp., 2016, 18, doi: 10.3791/53316.

[18] Marchetti C., Kristeleit R., McCormack M., Mould T., Olaitan A., Widschwendter M., et al.: “Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review”. Gynecol. Oncol., 2017, 144, 57.

[19] Tinquaut F., Freyer G., Chauvin F., Gane N., Pujade-Lauraine E., Falandry C.: “Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: Results of a pooled analysis of three GINECO phase II trials”. Gynecol. Oncol., 2016, 143, 22.

[20] Kubota E., Kataoka H., Hayashi K., Kamiya T., Sasaki M., Ogasawara N., et al.: “Advanced stomach and pancreas cancer successfully treated with combination chemotherapy with S-1/paclitaxel/lentinan”. Hepatogastroenterology, 2009, 56, 106.

[21] Sun M., Zhao W., Xie Q., Zhan Y., Wu B.: “Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer”. Surg. Oncol., 2015, 24, 28.

[22] Yin X., Ying J., Li L., Zhang H., Wang H.: “A meta-analysis of lentinan injection combined with chemotherapy in the treatment of nonsmall cell lung cancer”. Indian J. Cancer, 2015, 52, e29.

[23] Ye M., Zhou Y.: “Changes of regulatory T cells in pleural effusion of lung cancer patients with malignant pleural effusion undergoing cisplatin/lentinan treatment”. Zhejiang Medical Journal, 2014, 2, 124.

[24] Yoshino S., Watanabe S., Imano M., Suga T., Nakazawa S., Hazama S., et al.: “Improvement of QOL and prognosis by treatment of superfine dispersed lentinan in patients with advanced gastric cancer”. Hepatogastroenterology, 2010, 57, 172.

[25] Wang J., Li W., Huang X., Liu Y., Li Q., Zheng Z., et al.: “A polysaccharide from Lentinus edodes inhibits human colon cancer cell proliferation and suppresses tumor growth in athymic nude mice”. Oncotarget, 2016, 8, 610.

[26] Liu Q., Dong L., Li H., Yuan J., Peng Y., Dai S.: “Lentinan mitigates therarubicin-induced myelosuppression by activating bone marrowderived macrophages in an MAPK/NF-kappaB-dependent manner”. Oncol. Rep., 2016, 36, 315.

[27] Attia S.M., Harisa G.I., Abd-Allah A.R., Ahmad S.F., Bakheet S.A.: “The influence of lentinan on the capacity of repair of DNA damage and apoptosis induced by paclitaxel in mouse bone marrow cells”. J. Biochem. Mol. Toxicol., 2013, 27, 370.

[28] Zhang Z., Teruya K., Yoshida T., Eto H., Shirahata S.: “Fucoidan extract enhances the anti-cancer activity of chemotherapeutic agents in MDA-MB-231 and MCF-7 breast cancer cells”. Mar. Drugs, 2013, 11, 81.

[29] Ren M., Ye L., Hao X., Ren Z., Ren S., Xu K., et al.: “Polysaccharides from Tricholoma matsutake and Lentinus edodes enhance 5 fluorouracil-mediated H22 cell growth inhibition”. J. Tradit. Chin. Med., 2014, 34, 309.